Mesoblast Completes Treatment in Phase 3 Low Back Pain Trial
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
RMAT designation
Advertisement
Lexeo Therapeutics Advances LX2020 with FDA RMAT Designation
NEW YORK, August 5, 2026 Lexeo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Allogene Therapeutics Receives FDA RMAT Status for Cema-Cel
SOUTH SAN FRANCISCO, Calif., July 29, 2026 Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Mesoblast Completes Enrollment in Low Back Pain Trial
NEW YORK and MELBOURNE, July 13-14, 2026 Mesoblast Limited announced that it has achieved its target of treating at...
Advertisements
Cellectis Secures FDA RMAT Status for Lasme-cel
NEW YORK, June 9, 2026 Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine...
Mesoblast Completes Enrollment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, USA & MELBOURNE, Australia, April 28–29, 2026 Mesoblast Limited has announced that it has achieved the patient...
Orca Bio Secures FDA RMAT Status for Orca-Q Therapy
MENLO PARK, Calif., April 28, 2026 Orca Bio has announced that the U.S. Food and Drug Administration (FDA) has...
SENTI-202 AML Cell Therapy Completes Phase 1 Enrollment
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 — Senti Biosciences announced the completion of patient enrollment in its Phase...
FDA Grants RMAT Designation to Avobis Bio’s AVB-114 for Crohn’s Perianal Fistulas
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
Advertisement
